Tenofovir Alafenamide (Vemlidy) prior authorization at Molina Healthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Molina Healthcare requires prior-authorization documentation for Tenofovir Alafenamide (Vemlidy): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Molina Healthcare reviews Tenofovir Alafenamide (Vemlidy) prior authorizations against its medical policy . Molina Healthcare-specific context: Primary Medicaid MCO + ACA Marketplace in 21 states. 42 CFR Part 438 Subpart F applies. State Fair Hearing is the escalation path after internal MCO appeal.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Molina Healthcare's medical policy URL referenced in the cover letter
Molina Healthcare's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Medicaid MCO carve-outs
- Step therapy
- Specialty pharmacy denials
Tenofovir Alafenamide (Vemlidy)-specific denial patterns and context
Across payers (not just Molina Healthcare), Tenofovir Alafenamide (Vemlidy)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- PrEP coverage (now USPSTF Grade A — should be $0 cost-sharing under ACA §2713)
TAF — newer prodrug of tenofovir with better renal + bone safety. Component of Descovy (PrEP), Genvoya, Odefsey.
Manufacturer patient-assistance program: Gilead Advancing Access — relevant when a Molina Healthcare denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Molina Healthcare gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.molinahealthcare.com/providers) with the same packet plus a peer-reviewed citation supporting Tenofovir Alafenamide (Vemlidy)for the patient's indication.
Medicare Advantage path: if Molina Healthcare misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Molina Healthcare as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Molina Healthcare denial on DenialHelp.
Contact Molina Healthcare
- Provider portal: https://www.molinahealthcare.com/providers
Frequently asked questions
What documentation does Molina Healthcare need for Tenofovir Alafenamide (Vemlidy) prior auth?
Molina Healthcare's typical PA packet for Tenofovir Alafenamide (Vemlidy): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Molina Healthcare?
Standard Tenofovir Alafenamide (Vemlidy) PA decisions at Molina Healthcare: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Molina Healthcare most often reject Tenofovir Alafenamide (Vemlidy) for?
Across Molina Healthcare's book the common rejection patterns include: Medicaid MCO carve-outs; Step therapy; Specialty pharmacy denials. For Tenofovir Alafenamide (Vemlidy) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Molina Healthcare on Tenofovir Alafenamide (Vemlidy)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Tenofovir Alafenamide (Vemlidy) PA packet
Open ApprovalHelp — generate a Tenofovir Alafenamide (Vemlidy) prior-auth packet tailored to Molina Healthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com